{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T17:31:07Z","timestamp":1774027867984,"version":"3.50.1"},"reference-count":17,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2025,5,18]],"date-time":"2025-05-18T00:00:00Z","timestamp":1747526400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>McCune-Albright syndrome (MAS) is a rare mosaic disorder characterized by the classic triad of fibrous dysplasia of bone (FD), caf\u00e9-au-lait skin macules, and hyperfunctioning endocrinopathies. MAS is caused by a postzygotic mutation in the G-protein alpha subunit (GNAS) gene resulting in G-protein \u03b1-subunit somatic activation. There is no approved treatment for MAS. We present the case of a 43-yr-old male carpenter with severe polyostotic FD and adult-onset growth hormone (GH) excess who was treated with denosumab and somatostatin analog, complicated with a diagnosis of chronic myeloid leukemia (CML). The patient had multiple skeletal lesions, resulting in pain on movement and neurovascular compromise of the left arm. A forequarter amputation was considered to treat a large clavicular lesion, however, involvement of his thoracic cage resulted in significant cardiopulmonary impairment, including restrictive lung disease, and the surgery was deemed too risky. Denosumab was commenced after failed intravenous bisphosphonate for pain management, resulting in alleviation of pain. Screening of endocrinopathy revealed GH excess with an elevated Insulin-like Growth Factor-1 (IGF-1) level and 7\u00a0mm pituitary adenoma. Lanreotide was commenced as a medical therapy, resulting in a reduction in IGF-1 levels. Over 9\u00a0mo into the denosumab treatment, the patient was diagnosed with CML in the context of routine full blood examination. The patient achieved a hematological remission with imatinib. Polyostotic FD can lead to serious complications from deformities of the skeleton, including cardiopulmonary complications. This case represents a patient with a severe spectrum of MAS\/FD with a diagnosis of CML. We postulate that CML is unlikely due to the MAS, as the two have different pathogenic pathways. Denosumab is effective in pain management, however, it should be used with caution, and there are no large studies to guide long-term management. Evaluation and management of MAS should also include detailed endocrinopathy assessment and screening, even in adulthood.<\/jats:p>","DOI":"10.1093\/jbmrpl\/ziaf090","type":"journal-article","created":{"date-parts":[[2025,5,18]],"date-time":"2025-05-18T10:27:27Z","timestamp":1747564047000},"source":"Crossref","is-referenced-by-count":3,"title":["McCune-Albright syndrome: a case of an adult with fibrous dysplasia, severe cardiopulmonary complications, acromegaly, and chronic myeloid leukemia"],"prefix":"10.1093","volume":"9","author":[{"given":"Amanda","family":"Ji","sequence":"first","affiliation":[{"name":"Department of Diabetes and Endocrinology, Cairns Hospital , Cairns, QLD 4870 ,","place":["Australia"]},{"name":"Department of Endocrinology, Mater Hospital Brisbane , Brisbane, QLD 4101 ,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"McLean","sequence":"additional","affiliation":[{"name":"Department of Diabetes and Endocrinology, Cairns Hospital , Cairns, QLD 4870 ,","place":["Australia"]},{"name":"Menzies School of Health Research, Charles Darwin University , Darwin, NT 0811,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashim","family":"Sinha","sequence":"additional","affiliation":[{"name":"Department of Diabetes and Endocrinology, Cairns Hospital , Cairns, QLD 4870 ,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,5,18]]},"reference":[{"issue":"12","key":"2025062800180946200_ref1","doi-asserted-by":"publisher","first-page":"4957","DOI":"10.1210\/jc.2006-0561","article-title":"McCune-Albright syndrome and acromegaly: effects of hypothalamopituitary radiotherapy and\/or pegvisomant in somatostatin analog-resistant patients","volume":"91","author":"Galland","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"2025062800180946200_ref2","doi-asserted-by":"publisher","volume":"3","journal-title":"Orphanet J Rare Dis","DOI":"10.1186\/1750-1172-3-12"},{"issue":"1","key":"2025062800180946200_ref3","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s13023-019-1102-9","article-title":"Best practice management guidelines for fibrous dysplasia\/McCune-Albright syndrome: a consensus statement from the FD\/MAS international consortium","volume":"14","author":"Javaid","year":"2019","journal-title":"Orphanet J Rare Dis"},{"issue":"12","key":"2025062800180946200_ref4","doi-asserted-by":"publisher","first-page":"6069","DOI":"10.1210\/jc.2018-02543","article-title":"Denosumab in patients with fibrous dysplasia previously treated with bisphosphonates","volume":"104","author":"Majoor","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2025062800180946200_ref5","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1002\/jbmr.4380","article-title":"Safety of therapy with and withdrawal from denosumab in fibrous dysplasia and McCune-Albright syndrome: an observational study","volume":"36","author":"Meier","year":"2021","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2025062800180946200_ref6","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s00198-017-4217-7","article-title":"Bone marrow failure and extramedullary hematopoiesis in McCune-Albright syndrome","volume":"29","author":"Robinson","year":"2018","journal-title":"Osteoporos Int"},{"issue":"8","key":"2025062800180946200_ref7","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1056\/NEJMc2214862","article-title":"Safety and efficacy of denosumab for fibrous dysplasia of bone","volume":"388","author":"de Castro","year":"2023","journal-title":"N Engl J Med"},{"key":"2025062800180946200_ref8","doi-asserted-by":"publisher","first-page":"116819","DOI":"10.1016\/j.bone.2023.116819","article-title":"Denosumab use in bone fibrous dysplasia refractory to bisphosphonate: a retrospective multicentric study","volume":"174","author":"Trojani","year":"2023","journal-title":"Bone."},{"issue":"5","key":"2025062800180946200_ref9","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1210\/clinem\/dgab888","article-title":"Osteonecrosis of the jaw and antiresorptive agents in benign and malignant diseases: a critical review organized by the ECTS","volume":"107","author":"Anastasilakis","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2025062800180946200_ref10","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1002\/jbmr.1603","article-title":"Denosumab treatment for fibrous dysplasia","volume":"27","author":"Boyce","year":"2012","journal-title":"J Bone Miner Res"},{"issue":"11","key":"2025062800180946200_ref11","doi-asserted-by":"publisher","first-page":"e0285335","DOI":"10.1371\/journal.pone.0285335","article-title":"Risk of cancer in acromegaly patients: an updated meta-analysis and systematic review","volume":"18","author":"Xiao","year":"2023","journal-title":"PLoS One"},{"issue":"3","key":"2025062800180946200_ref12","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ando.2023.03.009","article-title":"Endocrine-related adverse conditions induced by tyrosine kinase inhibitors","volume":"84","author":"De Leo","year":"2023","journal-title":"Ann Endocrinol"},{"issue":"2","key":"2025062800180946200_ref13","doi-asserted-by":"publisher","first-page":"547","DOI":"10.4081\/oncol.2021.547","article-title":"The effect of imatinib and nilotinib on blood calcium and blood potassium levels in chronic myeloid leukemia patients: a literature review","volume":"15","author":"Prenggono","year":"2021","journal-title":"Oncol Rev"},{"issue":"6","key":"2025062800180946200_ref14","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1210\/jc.2013-3826","article-title":"Acromegaly and McCune-Albright syndrome","volume":"99","author":"Salenave","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2025062800180946200_ref15","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1210\/jc.2012-1274","article-title":"Somatic GNAS mutation causes widespread and diffuse pituitary disease in acromegalic patients with McCune-Albright syndrome","volume":"97","author":"Vortmeyer","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2025062800180946200_ref16","doi-asserted-by":"publisher","first-page":"5104","DOI":"10.1210\/jc.2001-012022","article-title":"Characterization of gsp-mediated growth hormone excess in the context of McCune-Albright syndrome","volume":"87","author":"Akintoye","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2025062800180946200_ref17","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1210\/jc.2013-3826","article-title":"Acromegaly and McCune-Albright syndrome","volume":"99","author":"Salenave","year":"2014","journal-title":"J Clin Endocrinol Metab"}],"container-title":["JBMR Plus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jbmrplus\/advance-article-pdf\/doi\/10.1093\/jbmrpl\/ziaf090\/63217909\/ziaf090.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article-pdf\/9\/7\/ziaf090\/63217909\/ziaf090.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article-pdf\/9\/7\/ziaf090\/63217909\/ziaf090.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T04:18:12Z","timestamp":1751084292000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article\/doi\/10.1093\/jbmrpl\/ziaf090\/8134333"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,18]]},"references-count":17,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,6,5]]}},"URL":"https:\/\/doi.org\/10.1093\/jbmrpl\/ziaf090","relation":{},"ISSN":["2473-4039"],"issn-type":[{"value":"2473-4039","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7]]},"published":{"date-parts":[[2025,5,18]]},"article-number":"ziaf090"}}